TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

28 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Fatty liver disease (NASH/MASH)

    A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

    Testing how efimosfermin alfa compares with placebo for MASH with scarred liver tissue

    💵 May compensate

    📍 GSK Investigational Site · Arcadia, CA · +39 more US sites · Get directions →

    The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Anxiety

    Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

    Testing a single oral dose medicine versus placebo for social anxiety in adults

    📍 Vanda Investigational Site · Phoenix, AZ · +30 more US sites · Get directions →

    This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • DepressionAnxiety

    Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome

    Studying how gut bacteria in pregnant people relates to depression and anxiety

    📍 Sunnybrook Health Science Center · Toronto, Ontario · Get directions →

    Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies.

    ✓ Study care freePhase 2Ages 18–43WomenLearn more →
  • DepressionAnxiety

    Nebulized Ketamine for the Treatment of Major Depressive Disorder

    Testing a breathing mist of ketamine to reduce symptoms of major depression

    📍 Maimonides Medical Center · Brooklyn, NY · Get directions →

    This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.

    ✓ Study care freePhase 3Ages 18–88Learn more →
  • Sickle cell disease

    The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

    Testing rilzabrutinib for safety and effectiveness in sickle-cell disease

    📍 University of Alabama at Birmingham- Site Number : 8400003 · Birmingham, AL · +15 more US sites · Get directions →

    This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B).

    ✓ Study care freePhase 3Ages 10–65Learn more →
  • DepressionAnxiety

    Creatine for Depressed Male and Female Methamphetamine Users

    Testing whether creatine helps depression and anxiety in people who use meth

    📍 Montana State University College of Nursing (Missoula campus) · Missoula, MT · Get directions →

    * Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression

    ✓ Study care freePhase 3Ages 18–59Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

    Testing a drug to treat fat buildup liver disease in people with stage 2 or 3 fibrosis

    📍 Akero Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.

    ✓ Study care freePhase 3Ages 18–80Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

    Testing whether two doses of pegozafermin are safe and work for liver scarring in adults with MASH

    📍 89bio Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.

    ✓ Study care freePhase 3Ages 18–80Learn more →
  • Anxiety

    📍 Servicios Especializados En Ensayos Clinicos, Seec, Sc · Mexico City, Mexico City · Get directions →

    To evaluate the superiority of cognitive behavioral therapy using the Aurora® digital medical device + conventional drug treatment, compared to conventional drug treatment alone, in reducing anxiety symptoms, as assessed by the change in the GAD-7 scale at 12 weeks of treatment, relative to baseline.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

    Testing whether pegozafermin is safe and works for MASH-related liver cirrhosis

    💵 May compensate

    📍 89bio Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Rheumatoid arthritis

    "Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"

    Testing whether vitamin E lowers inflammation and symptoms in rheumatoid arthritis

    📍 Civil Hospital of Guadalajara · Guadalajara, Jalisco · Get directions →

    The objective of this clinical trial is to determine whether α-tocopherol (vitamin E) supplementation decreases inflammation and clinical activity in patients with rheumatoid arthritis (RA).The main questions to be answered are: * Is supplementation with vitamin E (α-tocopherol) for one month associated with decreased clinical activity and inflammation in patients with RA? Researchers will compare α-tocopherol with a placebo (a look-alike substance containing no active ingredient) to see if α-tocopherol effectively reduces inflammation and clinical activity in patients with rheumatoid arthritis.

    ✓ Study care freePhase 2Ages 18+WomenLearn more →
  • Sickle cell disease

    Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

    Testing a single pneumococcal vaccine dose in children with sickle cell disease

    📍 Site # 8400006 · Atlanta, GA · +4 more US sites · Get directions →

    The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.

    ✓ Study care freePhase 3Ages 2–17Learn more →
  • DepressionAnxiety

    Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)

    Testing a cognitive training program to see brain and thinking changes in people with depression or

    📍 UC San Diego · San Diego, CA · Get directions →

    The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to one of two groups.

    ✓ Study care freePhase 2Ages 21–55Learn more →
  • Sickle cell disease

    A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

    Testing long-term treatment with a new medicine for sickle cell or thalassaemia

    📍 Univ of Alabama Birmingham · Birmingham, AL · +38 more US sites · Get directions →

    Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin.

    ✓ Study care freePhase 3Ages 2+Learn more →
  • Anxiety

    Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder

    Testing cannabidiol added to talk therapy for adults with generalized anxiety

    📍 Wayne State University School of Medicine, Tolan Park Medical Building · Detroit, MI · Get directions →

    This randomized, double-blind, placebo-controlled clinical trial investigates the use of Food and Drug Administration (FDA)-approved cannabidiol (EPIDIOLEX®) as an adjunct to cognitive behavioral therapy (CBT) in adults with generalized anxiety disorder (GAD). The study aims to evaluate whether cannabidiol-assisted CBT enhances emotion regulation via dorsomedial prefrontal cortex (dmPFC) activation and improves anxiety symptom outcomes compared to CBT with placebo.

    ✓ Study care freePhase 3Ages 18–45Learn more →
  • Sickle cell disease

    📍 University Of Alabama · Birmingham, AL · +13 more US sites · Get directions →

    A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.

    ✓ Study care freePhase 3Ages 12–100Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

    Testing a medicine called efruxifermin in people with compensated liver scarring from NASH/MASH

    💵 May compensate

    📍 Akero Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.

    ✓ Study care freePhase 3Ages 18–80Learn more →
  • Rheumatoid arthritis

    Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

    Studying which factors predict response in rheumatoid arthritis patients treated with DMARDs

    📍 University of Nebraska Medical Center · Omaha, NE · Get directions →

    Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure.

    ✓ Study care freePhase 3Ages 19+Learn more →
  • Sickle cell disease

    A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

    Testing how well etavopivat lowers painful sickle cell crises and organ damage

    📍 Uni of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo.

    ✓ Study care freePhase 3Ages 12+Learn more →
  • Fatty liver disease (NASH/MASH)

    LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

    Testing whether survodutide helps adults with MASH and moderate to advanced liver scarring

    💵 May compensate

    📍 University of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Testing whether survodutide helps adults with NASH/MASH cirrhosis

    💵 May compensate

    📍 The Institute for Liver Health II DBA Arizona Clinical Trials · Peoria, AZ · +39 more US sites · Get directions →

    This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Rheumatoid arthritis

    RA-PRO PRAGMATIC TRIAL

    Testing different treatment options for people with rheumatoid arthritis who are still active

    📍 East Alabama Arthritis Center PC · Auburn, AL · +39 more US sites · Get directions →

    The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another TNFi-biologic, i.e., a second TNFi-biologic first.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

    Testing the safety of an injected medicine in people with MASH and F2 or F3 scarring

    💵 May compensate

    📍 GSK Investigational Site · Arcadia, CA · +39 more US sites · Get directions →

    This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

    Testing whether a protein supplement reduces liver fat in teens with obesity

    📍 Univeristy of Colorado Anschutz Medical Campus · Aurora, CO · Get directions →

    Participants 13-18 years of age with extra fat stored in the liver will be randomly assigned to a protein supplement or placebo "fake supplement" for 2 months to see if the participants who get the protein supplement have less fat in the liver compared to participants who were in the placebo group. After the 2 month intervention, all participants can continue the study and will all receive the protein supplement for an additional 10-months.

    ✓ Study care freePhase 3Ages 13–18Learn more →
  • Fatty liver disease (NASH/MASH)

    Estrogen Administration for the Treatment of NASH in Postmenopausal Women

    Testing estrogen to treat nonalcoholic fatty liver disease in women after menopause

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic in the United States. Despite this, the treatment options remain limited.

    ✓ Study care freePhase 3Ages 45–70WomenLearn more →
  • Sickle cell disease

    A Phase 2/3 Study in Adult and Adolescent Participants With SCD

    Testing safety and how well a treatment works for sickle cell in teens and adults

    📍 Smilow Cancer Hospital · New Haven, CT · +23 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.

    ✓ Study care freePhase 2Ages 12+Learn more →
  • DepressionAnxiety

    Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer

    Testing combined sleep treatments to improve sleep and mood in people with advanced cancer

    📍 MD Anderson Cancer Center · Houston, TX · Get directions →

    To learn if Cognitive Behavior Therapy (called CBT), combined with either Bright Light Therapy (called BLT), methylphenidate, and/or melatonin, can help improve sleep and other related symptoms such as fatigue, anxiety, and depression in cancer patients. This is an investigational study.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Sickle cell disease

    Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

    Testing the safety and effectiveness of a one-time gene-edited cell treatment for severe sickle cell

    📍 New York Presbyterian Hospital - Morgan Stanley Children's Hospital · New York, NY · +2 more US sites · Get directions →

    This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.

    ✓ Study care freePhase 3Ages 12–35Learn more →